Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: A 4 week randomized multicentre controlled trial
- Authors
- Yoo, S.H.; Park, S.H.; Song, J.S.; Kang, K.H.; Park, C.S.; Yoo, J.H.; Choi, B.W.; Hahn, M.H.
- Issue Date
- 2001
- Keywords
- Leukotriene receptor antagonist; Mild-to-moderate asthma; Pranlukast; Randomized clinical trial
- Citation
- Respirology, v.6, no.1, pp 15 - 21
- Pages
- 7
- Journal Title
- Respirology
- Volume
- 6
- Number
- 1
- Start Page
- 15
- End Page
- 21
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/26310
- DOI
- 10.1046/j.1440-1843.2001.00291.x
- ISSN
- 1323-7799
1440-1843
- Abstract
- Objective: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. Methodology: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with β2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. Results: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n=98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of β2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 ± 10.1 L/min at baseline, 394.5 ± 10.1 at week 2, 396.3 ± 10.4 at week 4). There were no serious adverse reactions. Conclusion: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.